An Open Label, Multicentre, Phase Ib/II Study of BGB324 Administered as a Single Agent or in Combination with Cytarabine or Decitabine in Patients with Acute Myeloid Leukemia or as a Single Agent in Patients with Myelodysplastic Syndrome
The goal of this research study is to find the highest tolerable dose of BGB324 that can be given to patients with AML. Another goal of this study is to learn if the highest tolerable dose can help to control AML.
Treatment Location: N/A
IRB Review and Approval Date: 02/26/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: